Topic Archives: Thermo Fisher Scientific (TMO)

This is the latest teaser pitch that a lot of folks have been asking about — and rightly so, I expect, because it’s designed to be extremely topical and get you revved up immediately. Here’s the intro to the ad that I’ve seen in some Angel Publishing newsletters: “We’re now in crisis mode over coronavirus […]

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. You can see his past articles and biography here.] “Many things you hear in this room are untrue.” (sign posted in Yale-New Haven Medical Center physician cafeteria) […]

This article originally ran on January 12… the teaser pitch was still being circulated heavily last week, and the stock released earnings on February 3 that disappointed investors, bringing shares down about 15% (it was teased as a “$7 biotech,” and briefly $8, before then). The original Jan. 14 “special event” catalyst teased by Lichtenfeld, […]

[ed note: Dr. KSS is a paid contributor to Stock Gumshoe who writes about biotech stocks for (and discusses them with) the Irregulars. He chooses his own topics, and his words and opinions are his alone. Enjoy!] Greetings fellow Irregulars!  You’ve all been waiting for it….our first-ever annual ceremony in which we look back on […]

These are my notes and instant reactions from a presentation at the Value Investing Congress, the notes below might contain errors, paraphrases, incorrect quotes, or misinterpretations. Leon Cooperman is probably known to most of you, he may well be the biggest “CNBC name” at today’s session — he runs Omega Advisors, a $10 billion partnership/hedge […]

[Ed. Note: Dr. KSS writes about medical topics and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his thoughts and words are his own. Enjoy!] Here we are, solidly in the postmodern 21st century, “so late in the goddam day,” as one of novelist Martin Amis’s characters says, and what […]

Comments

  • Travis Johnson, Stock Gumshoe

    Finally worked out for hopeful PACB shareholders... as long as you didn't buy during late 2015 or 2016. I have no idea ...

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

    Connect with Travis

    website designed by Gravity Switch